Abstract:Gastric cystica profunda (GCP) is a rare disease characterized by multiple cystic lesions in the mucosa and/or submucosal layer. Usually, GCP occurs in stomachs that have previously been operated on.If there is no postoperative pathological results, it is challenging to diagnose GCP based on nonspecific clinical symptoms and imaging findings. This report aimed to provide a comprehensive overview of all cases of GCP reported to date. A comprehensive literature search was conducted for all reported GCP cases bet… Show more
“…Gastritis cystica profunda (GCP) is a rare disease first described in 1972 ( 5 ). GCP is characterized by hyperplasia and cystic dilatation of gastric glands that extend into the submucosa ( 6 ). The cystic expansion may also occur in the mucosa and/or muscularis propria in some cases, while in others the mucosa may appear normal ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…GCP is characterized by hyperplasia and cystic dilatation of gastric glands that extend into the submucosa ( 6 ). The cystic expansion may also occur in the mucosa and/or muscularis propria in some cases, while in others the mucosa may appear normal ( 6 , 7 ). GCP is difficult to diagnose preoperatively owing to nonspecific symptoms and radiographic appearances, and most of the 52 patients reported so far underwent surgical excision.…”
Section: Introductionmentioning
confidence: 99%
“…GCP is difficult to diagnose preoperatively owing to nonspecific symptoms and radiographic appearances, and most of the 52 patients reported so far underwent surgical excision. There is currently no evidence of recurrence or metastasis, suggesting a benign course ( 6 ). However, GCP was reported to show elevated proliferation and DNA repair and occur in 3% gastric carcinomas ( 6 ), and several cases have shown early gastric cancer associated with GCP, including three in which an adenocarcinoma (ADC) was partially within GCP.…”
Section: Introductionmentioning
confidence: 99%
“…There is currently no evidence of recurrence or metastasis, suggesting a benign course ( 6 ). However, GCP was reported to show elevated proliferation and DNA repair and occur in 3% gastric carcinomas ( 6 ), and several cases have shown early gastric cancer associated with GCP, including three in which an adenocarcinoma (ADC) was partially within GCP. Therefore, GCP is generally regarded as a precursor of gastric tumor ( 6 , 8 ).…”
Genomic rearrangements involving
EWSR1
and the
CREB
family of transcription factors are increasingly detected in an array of mesenchymal neoplasms, most of which are malignant. Gastritis cystica profunda (GCP) is a rare disease characterized by cystic dilatation of gastric glands into the submucosa and generally regarded as a precursor to tumor. Herein, we report a peculiar case in which an
EWSR1-CREM
-rearranged gastric mesenchymal tumor was admixed with GCP in a 64-year-old woman. All layers of the gastric wall were invaded, although no lymph node or neural invasion, or tumoral vascular emboli was noted. The mass showed readily distinguishable epithelial and mesenchymal components. The epithelial component consisted mainly of glandular structures with some showing metaplastic growth. The epithelial cells showed focally atypical hyperchromatic nuclei, slightly eosinophilic cytoplasm, and infrequent mitosis. The mesenchymal component consisted of monomorphic, ovoid-shaped cells with scanty cytoplasm, regular nuclei, and rare mitotic figures. Immunohistochemically, the epithelial cells were uniformly positive for cytokeratins, and the mesenchymal neoplasm showed focal positivity for CD10, CD117 and CD56. An
EWSR1
-
CREM
fusion was identified with genomic profiling and confirmed with fluorescence in situ hybridization (FISH) in the tumor. Given the low mitotic activity, absence of nodal or distant spread and vascular or neural invasion, and disease-free status at 28-month follow-up, both lesions were likely benign. To our knowledge, this is the first to report an
EWSR1-CREM
fusion in a gastric mesenchymal tumor with accompanying GCP.
“…Gastritis cystica profunda (GCP) is a rare disease first described in 1972 ( 5 ). GCP is characterized by hyperplasia and cystic dilatation of gastric glands that extend into the submucosa ( 6 ). The cystic expansion may also occur in the mucosa and/or muscularis propria in some cases, while in others the mucosa may appear normal ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…GCP is characterized by hyperplasia and cystic dilatation of gastric glands that extend into the submucosa ( 6 ). The cystic expansion may also occur in the mucosa and/or muscularis propria in some cases, while in others the mucosa may appear normal ( 6 , 7 ). GCP is difficult to diagnose preoperatively owing to nonspecific symptoms and radiographic appearances, and most of the 52 patients reported so far underwent surgical excision.…”
Section: Introductionmentioning
confidence: 99%
“…GCP is difficult to diagnose preoperatively owing to nonspecific symptoms and radiographic appearances, and most of the 52 patients reported so far underwent surgical excision. There is currently no evidence of recurrence or metastasis, suggesting a benign course ( 6 ). However, GCP was reported to show elevated proliferation and DNA repair and occur in 3% gastric carcinomas ( 6 ), and several cases have shown early gastric cancer associated with GCP, including three in which an adenocarcinoma (ADC) was partially within GCP.…”
Section: Introductionmentioning
confidence: 99%
“…There is currently no evidence of recurrence or metastasis, suggesting a benign course ( 6 ). However, GCP was reported to show elevated proliferation and DNA repair and occur in 3% gastric carcinomas ( 6 ), and several cases have shown early gastric cancer associated with GCP, including three in which an adenocarcinoma (ADC) was partially within GCP. Therefore, GCP is generally regarded as a precursor of gastric tumor ( 6 , 8 ).…”
Genomic rearrangements involving
EWSR1
and the
CREB
family of transcription factors are increasingly detected in an array of mesenchymal neoplasms, most of which are malignant. Gastritis cystica profunda (GCP) is a rare disease characterized by cystic dilatation of gastric glands into the submucosa and generally regarded as a precursor to tumor. Herein, we report a peculiar case in which an
EWSR1-CREM
-rearranged gastric mesenchymal tumor was admixed with GCP in a 64-year-old woman. All layers of the gastric wall were invaded, although no lymph node or neural invasion, or tumoral vascular emboli was noted. The mass showed readily distinguishable epithelial and mesenchymal components. The epithelial component consisted mainly of glandular structures with some showing metaplastic growth. The epithelial cells showed focally atypical hyperchromatic nuclei, slightly eosinophilic cytoplasm, and infrequent mitosis. The mesenchymal component consisted of monomorphic, ovoid-shaped cells with scanty cytoplasm, regular nuclei, and rare mitotic figures. Immunohistochemically, the epithelial cells were uniformly positive for cytokeratins, and the mesenchymal neoplasm showed focal positivity for CD10, CD117 and CD56. An
EWSR1
-
CREM
fusion was identified with genomic profiling and confirmed with fluorescence in situ hybridization (FISH) in the tumor. Given the low mitotic activity, absence of nodal or distant spread and vascular or neural invasion, and disease-free status at 28-month follow-up, both lesions were likely benign. To our knowledge, this is the first to report an
EWSR1-CREM
fusion in a gastric mesenchymal tumor with accompanying GCP.
“…Simple GCP can manifest as a submucosal tumor or polypoid or simulating EGC, which is similar to a previous report. 10 About one-third of the GCP coexisted with tumorous lesions. Another report included two cases of GCP without a history of surgery in 2010.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.